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Introduction
Percutaneous coronary intervention (PCI) has transformed the 
treatment of coronary artery disease (CAD) (1–3). The major 
drawback of this procedure is restenosis, which is caused by inti-
mal hyperplasia triggered during arterial wall injury with con-
current endothelial denudation (4). Restenosis primarily results 
from the proliferation and migration of vascular smooth muscle 
cells (VSMCs) into the intima, eventually leading to renarrowing 
of the lumen (4, 5). Previous studies demonstrated that siroli-
mus (rapamycin), a macrocyclic triene antibiotic (6, 7), inhibits 
VSMC proliferation and migration by inhibiting the downregula-
tion of p27Kip1 (p27), a well-established cell-cycle regulator (8, 9). 
Such a discovery led to the development of the first sirolimus-
coated stents. These drug-eluting stents (DES), quickly followed 
by other devices capable of delivering in situ antiproliferative 
agents (known as first- and second-generation DES), significantly 
reduced the clinical incidence of restenosis in comparison with 
bare-metal stents (BMS), revolutionizing the field of PCI (3, 10). 
However, all drugs currently approved to coat DES do not discrim-
inate between proliferating VSMCs and endothelial cells (ECs), 
thus delaying reendothelialization and subsequent vascular heal-
ing (11–15). This lack of drug specificity has greatly increased the 
risk of neoatherosclerosis and late thrombosis, potentially cata-
strophic events primarily caused by incomplete endothelial cov-
erage of the treated vessel (15–18). These noteworthy health risks 
unfortunately require patients to endure prolonged regimens 
of dual-antiplatelet therapy following PCI (3, 19). A functional 
endothelium is critical for the regulation of vascular tone, sup-
pression of intimal hyperplasia, neoatherosclerosis, and thrombi 
formation, and the reduction of dual-antiplatelet regimens (16, 
20). Accordingly, an ideal therapy would selectively inhibit VSMC 
proliferation without affecting EC function (21). In this study, we 
investigated whether a microRNA-based (miRNA-based) strategy 
could be used as a selective therapy, inhibiting VSMC proliferation 
and hence neointimal hyperplasia, while simultaneously promot-
ing vessel reendothelialization and preservation of EC function.
The discovery of miRNAs, a class of endogenous, small non-
coding RNAs, represents a crucial breakthrough in the study 
of gene regulation. MiRNAs use base pairing to direct RNA- 
induced silencing complexes to specific mRNA transcripts con-
taining partially or fully complementary sequences, result-
ing in the degradation or translational inhibition of the target 
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Next, we transduced primary human ECs and VSMCs (30 
PFU/cell) with the 3 Ad vectors to assess protein expression lev-
els of p27, GFP (to evaluate transduction efficiency), and GAPDH 
(loading control). Immunoblot analysis revealed that p27 was 
highly overexpressed in VSMCs and ECs transduced with Ad-p27 
(Figure 1C). VSMCs, which express very low levels of endoge-
nous miR-126-3p, showed high overexpression of p27 after 
transduction with Ad-p27-126TS (Figure 1C). Conversely, in ECs 
transduced with Ad-p27-126TS, we found that p27 overexpres-
sion was diminished, most likely due to endogenous endothelial 
miR-126-3p binding to its 4 target sequences at the 3′ end of the 
exogenous p27 transcript, thereby leading to its degradation and/
or inhibition of translation (Figure 1C). To ensure that the 4 target 
sequences for miR-126-3p did not act as “sponges” for endoge-
nous miR-126-3p or its sister strand miR-126-5p, we transduced 
ECs with a higher number of particles (50 PFU/cell) of each of 
the 3 Ad vectors, and we assessed endogenous miR-126-3p and 
miR-126-5p levels as well as the miR-126-3p target gene PIK3R2 
by RT-qPCR (30). In Ad-p27–transduced ECs, miR-126-3p expres-
sion levels were comparable to those in Ad-GFP–transduced cells, 
whereas Ad-p27-126TS–transduced ECs exhibited a slight reduc-
tion (~20%) in endogenous miR-126-3p expression (Supplemental 
Figure 1A; supplemental material available online with this arti-
cle; doi:10.1172/JCI76069DS1). We observed no significant dif-
ferences in expression levels of PIK3R2 (Supplemental Figure 1B) 
or miR-126-5p (Supplemental Figure 1C) among ECs transduced 
with the 3 Ad vectors. These results are in agreement with previ-
ous reports showing that 4 tandem repeat copies of a single target 
element are effective in the silencing of gene expression, while 
concurrently minimizing the saturation of miRNAs (28, 31–33).
Since Ad-p27-126TS led to an overexpression of p27 in VSMCs 
but not  ECs, we tested whether Ad-p27-126TS would consequently 
inhibit VSMC proliferation without affecting ECs. Ad-p27 inhibited 
the proliferation of both cell types by more than 70% (Figure 1D). 
Importantly, the proliferation of VSMCs transduced with Ad-p27-
126TS was also inhibited by more than 70%, whereas EC prolifer-
ation was unchanged (Figure 1D). Similarly, we tested the effect of 
transduction with the 3 Ad vectors on the migration of VSMCs and 
ECs in a wound-scratch assay. VSMCs and ECs transduced with 
Ad-p27 displayed greater than 75% inhibition of migration (Fig-
ure 2, A and B). Interestingly, transduction with Ad-p27-126TS led 
to the inhibition of VSMC migration by more than 70%, while EC 
migration was not inhibited (Figure 2, A and B). Then, we examined 
EC behavior following transduction using a network formation 
assay. ECs transduced with Ad-p27 displayed a marked decrease in 
network-like formation, whereas Ad-p27-126TS–transduced ECs 
formed networks comparable to those observed in ECs transduced 
with control Ad-GFP (Figure 2C). Finally, we performed a platelet 
adhesion assay to test the integrity of ECs and their antithrombotic 
phenotype in vitro. Compared with Ad-GFP, ECs transduced with 
Ad-p27 displayed a significant increase in platelet aggregation, 
while ECs transduced with Ad-p27-126TS showed minimal levels 
of platelet adhesion (Figure 2D).
Taken together, these data demonstrate that by inserting 4 tar-
get sequences for the EC-specific miR-126-3p at the 3′ end of p27, 
it is possible to overexpress exogenous p27 in VSMCs and thereby 
inhibit their capacity for proliferation and migration. Meanwhile, 
mRNA. They are active in most biological processes, including 
neointimal formation (22–24), and are expressed in tissue- and 
cell-specific patterns. In particular, miR-126, a pivotal regulator 
of vascular integrity and angiogenesis, is highly expressed in ECs 
(25, 26). MiR-126 is encoded within the seventh intron of the 
EC-specific gene epidermal growth factor–like domain 7 (Egfl7), 
which is critical for blood vessel formation and is upregulated 
in arterial injury sites and atherosclerotic plaques (27). The pre-
cursor miRNA pre–miR-126 is cleaved into 2 mature strands, 
miR-126-3p and miR-126-5p, two of the most abundant miRNAs 
in ECs (25, 26). Notably, lack of miR-126-5p, but not miR-126-3p, 
has been recently shown to impair endothelial recovery after 
denudation in Mir126–/– mice (26).
Endogenous miRNAs are remarkably effective in regulating 
transgene expression when tagged with artificial miRNA tar-
get sequences, according to the activity of the given miRNA (28, 
29). In this study, we took advantage of the EC-specific miR-126 
to design a unique adenoviral (Ad) vector, encoding the cell-
cycle inhibitor p27 and incorporating 4 complementary target 
sequences for the mature miR-126-3p strand at its 3′ end (Ad-p27-
126TS). Our aim was to overexpress exogenous p27, yet effectively 
regulate its overexpression in a cell-specific manner with the incor-
porated EC-specific miR-126-3p target sequences. Consequently, 
we hypothesized that exogenous p27 overexpression would be 
permitted in VSMCs, but not ECs, enhancing the degree of reen-
dothelialization and restoration of EC function following injury. 
To evaluate our strategy, we quantified the effects of p27 overex-
pression with and without miR-126-3p target sequences on the 
proliferation and migration of VSMCs and ECs, as well as network 
formation and platelet aggregation in ECs. We further examined 
the in vivo effects of our approach on neointimal formation, sur-
face reendothelialization, hypercoagulability, and EC function in 
a rat model of arterial balloon injury. Our results demonstrate that 
adding miR-126-3p target sequences to the 3′ end of exogenous 
p27 not only selectively protects ECs from p27 overexpression, but 
also allows for complete reendothelialization and preservation of 
EC function in vivo. This initial proof-of-principle study provides 
the first step toward a novel therapeutic strategy to improve vascu-
lar healing and prevent late thrombosis following PCI.
Results
A unique Ad vector incorporating miR-126-3p target sequences selec-
tively protects ECs from the antiproliferative and antimigratory effects 
of exogenous p27. Since we sought to leverage the EC-specific pat-
tern of miR-126-3p expression, we first assessed the expression 
level of endogenous miR-126-3p in primary ECs and in VSMCs 
by real-time quantitative PCR (RT-qPCR). ECs showed greater 
than 600-fold higher expression of miR-126-3p compared with 
that detected in VSMCs (Figure 1A). To selectively overexpress 
exogenous p27 in VSMCs and not ECs, we designed the following 
Ad vectors, as illustrated in Figure 1B: (a) Ad-p27, a p27 expres-
sion cassette driven by a CMV promoter; (b) Ad-p27-126TS, a p27 
expression cassette driven by a CMV promoter containing 4 tan-
dem copies of a 22-bp target sequence perfectly complementary 
to the mature miR-126-3p strand at the 3′ end of p27; (c) Ad-GFP, 
a control CMV-GFP Ad vector. All 3 vectors contained GFP under 
the control of a CMV promoter.
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composed of VSMCs (Figure 3B). Further staining for collagen 
and elastin in Ad-p27– and Ad-p27-126TS–transduced vessels 
indicated that p27 overexpression resulted in no undesirable 
fundamental alteration in the arterial structure (Supplemental 
Figure 5, A and B). These data indicate that both Ad-p27 and 
Ad-p27-126TS inhibited neointimal formation in vivo.
Ad-p27-126TS restores reendothelialization. We and others have 
previously demonstrated that overexpression of exogenous p27 
inhibits not only VSMC, but also EC proliferation and migration 
(38, 39). Here, we assessed the endothelial integrity of carotid 
arteries injured and transduced with the 3 Ad vectors. EC-specific 
VE-cadherin (40) immunostaining was performed in longitudinal 
en face arterial preparations at 2 (Figure 4 and Supplemental Vid-
eos 1–4) and 4 weeks after injury (Supplemental Figure 6 and Sup-
plemental Videos 5–7). The negative control (secondary antibody 
only) is depicted in Supplemental Figure 7 and Supplemental Video 
8. Tridimensional evaluation revealed that Ad-GFP–transduced 
vessels displayed an irregular neointimal surface, presumably due 
to the severe restenotic process, with uneven endothelial coverage 
(Figure 4, A–D, Supplemental Figure 6, A and B, and Supplemental 
Videos 1, 2, and 5). Neither Ad-p27– nor Ad-p27-126TS–transduced 
arteries exhibited restenosis (Figure 4, E–H, Supplemental Figure 
6, C–F, and Supplemental Videos 3, 4, 6, and 7). Strikingly, while 
Ad-p27–transduced vessels exhibited incomplete reendothelializa-
tion 2 and 4 weeks after injury (26% and 29% coverage compared 
with uninjured controls, respectively), Ad-p27-126TS–transduced 
vessels displayed extensive, uniform endothelial coverage (80% 
and 88%, respectively), as shown in Figure 4, G–I, and Supple-
mental Figure 6, E–G. These results were confirmed by scanning 
electron microscopy, showing a completely irregular internal sur-
face in Ad-GFP–transduced vessels and a lack of endothelial cov-
erage in Ad-p27–transduced vessels (Figure 4J), which displayed 
fibrotic remodeling that became more evident 4 weeks after 
injury (Supplemental Figure 6H). Conversely, transduction with 
ECs displayed a nonthrombogenic phenotype, with preserved 
ability to proliferate, migrate, and form network-like structures.
Ad-p27-126TS inhibits neointimal formation in vivo. To test our 
approach in vivo, we used the rat carotid artery balloon injury 
model, transducing the vessel with the 3 different Ad vectors (34). 
Since the arterial wall heals within 28 days following stent implanta-
tion in animal models (4), we assessed the efficacy of our approach 
at 2 and 4 weeks after injury. Ad transduction efficiency was eval-
uated by GFP immunostaining of arterial sections using a Cy3- 
conjugated antibody. All arteries transduced with Ad-GFP, Ad-p27, 
or Ad-p27-126TS were GFP positive (Supplemental Figure 2, A and 
B). These findings are consistent with previous reports showing 
GFP expression in vivo 2 and 4 weeks after Ad transduction (35). 
To ascertain that Ad transduction was localized to the injury sites 
of the right carotid arteries and did not spread systemically, we 
performed GFP immunostaining of sections of the contralateral 
carotid artery. These sections were negative for GFP expression 
(Supplemental Figure 2A, uninjured). Moreover, we verified p27 
overexpression in the carotid wall by immunoblot analysis of the 
vessel 3 days after transduction (Supplemental Figure 3). These 
data indicate that the in vivo Ad-mediated transductions were effi-
cient and localized to the injured vessels.
Ad-mediated overexpression of p27 in balloon-injured arter-
ies has been shown to inhibit restenosis (36, 37). To test whether 
Ad-p27-126TS would have comparable inhibitory effects on 
neointimal formation in vivo, we determined the intima/media 
ratios in carotid arteries 2 and 4 weeks after injury. We found 
that carotid arteries transduced with Ad-GFP exhibited a sig-
nificant increase in the intima/media ratio compared with that 
in uninjured control vessels (Figure 3A and Supplemental Figure 
4). Notably, transduction with both Ad-p27 and Ad-p27-126TS 
inhibited neointimal formation to a similar degree (Figure 3A 
and Supplemental Figure 4). Immunostaining for α-smooth mus-
cle actin (α-SMA) confirmed that the neointima was primarily 
Figure 1. miR-126-3p target sequences selectively pro-
tect ECs from the antiproliferative effects of p27. (A) 
RT-qPCR analysis of miR-126-3p expression. (B) Sche-
matic representation of the p27 expression cassette 
in the Ad vectors engineered to inhibit overexpression 
of exogenous p27 in cells expressing miR-126-3p (i.e., 
ECs). (C) Representative immunoblot of p27 protein 
expression from 3 independent experiments accompa-
nied by densitometric quantification. Lanes were run 
on the same gel but were noncontiguous. For each cell 
type, p27 expression was normalized to each vector’s 
GFP expression to account for transduction efficiency. 
(D) Proliferation assays of VSMCs and ECs transduced 
with the indicated Ad vector. Data represent the mean 
± SEM of at least 3 experiments performed in qua-
druplicate. Data comparisons were made using 1-way 
ANOVA with Tukey-Kramer’s post hoc test. *P < 0.01 
versus VSMCs (A); *P < 0.01 versus Ad-GFP (C and D).
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Figure 2. Ad-p27-126TS inhibits VSMC migration while preserving EC properties in vitro. Migration assays of VSMCs (A) and ECs (B) transduced with the 
indicated Ad vector. Representative images at the indicated time points are shown. Wound areas were measured using ImageJ64 software. (C) Formation of 
network-like structures in ECs was quantified by counting branch points. Scale bars: 100 μm (A–C). Data represent the means ± SEM of at least 3 experiments 
performed in quadruplicate. (D) Representative photomicrographs of platelet adhesion to ECs transduced with the indicated Ad vector in a parallel-plate flow 
chamber apparatus before (upper panels, t = 0) and after perfusion of PPACK-treated blood and washing (lower panels, t = 3 minutes). Yellow arrows represent 
human platelets. Scale bars: 30 μm. Graph on the right represents a quantification of the platelet adhesion test performed using Fiji software. Data represent 
the means ± SEM of at least 3 experiments performed in triplicate. Data comparisons were made using 1-way ANOVA with Tukey-Kramer’s post hoc test.  
*P < 0.01 versus Ad-GFP.
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Discussion
Clinical use of DES, with their controlled release of antiprolifera-
tive agents, has significantly reduced the incidence of restenosis 
following PCI in comparison with BMS use (3). However, their 
lack of drug specificity inhibits the proliferation and migration of 
both VSMCs and ECs in the vessel (11). While this nonselective 
drug action does inhibit neointimal hyperplasia, it effectively 
impairs the endothelial regeneration that is critical to vascular 
healing. Indeed, pathological studies have demonstrated that 
the delayed and insufficient reendothelialization common to 
both first- and second-generation DES directly contributes to 
objectionably high rates of uncovered struts, late thrombosis, 
and neoatherosclerosis (16, 41). The current study shows an 
innovative proof-of-principle approach to overcome the limita-
tions and risks associated with currently available devices. We 
report here the first miRNA-based strategy to our knowledge 
to selectively inhibit VSMC proliferation and migration for 
the prevention of restenosis, without concurrently inhibiting 
reendothelialization and EC function. We uniquely leveraged 
EC-specific miR-126 to design an Ad vector containing target 
sequences complementary to the mature miR-126-3p strand at 
the 3′ end of p27 in order to overexpress exogenous p27 in VSMCs, 
selectively preserving ECs. Our strategy is based on previous 
reports that indicated the feasibility of suppressing transgene 
expression up to 100-fold using properly engineered target sites 
for a highly expressed miRNA (28, 32). Therefore, we exploited 
the endogenous, tissue-specific expression of miR-126-3p with-
out affecting the bioactivity of miR-126-5p reported in ECs (26).
To our knowledge, no previous evidence suggests that 
miR-126 is endogenously expressed in VSMCs. However, we 
cannot discount the recent findings that miR-126 is secreted by 
ECs and transferred to VSMCs (42). Even so, the reported lev-
els of transmitted miR-126 in VSMCs remained insufficiently 
low in both in vitro cocultures with ECs and in vivo shear 
stress conditions to impede our strategy. Nevertheless, to val-
idate our approach, we first confirmed the lack of endogenous 
miR-126-3p expression in VSMCs and its endothelial specificity. 
We assessed the level of endogenous miR-126-3p via RT-qPCR 
and found it to be 600-fold higher in ECs compared with the 
levels detected in VSMCs in vitro. This significant difference 
strengthened our assumption that the level of endogenous 
miR-126-3p expression displayed by ECs was sufficient to bind 
the target sequences introduced by the Ad vector and effec-
tively inhibit exogenous p27 overexpression and its effects on 
ECs. Conversely, VSMCs lacking endogenous miR-126-3p per-
mitted overexpression of exogenous p27.
In healthy arteries, p27 is constitutively expressed in quies-
cent VSMCs (5). As a member of the Cip/Kip family of cyclin- 
dependent kinase (CDK) inhibitors, p27 binds and modulates 
cyclin D–, E– and A–dependent kinases, resulting in G1/S tran-
sition failure and cell-cycle arrest (5). The inhibitory effects of 
p27 in the arterial wall have been shown to be more potent than 
those of other members of the CDK inhibitors, including p21Cip1 
and p16Ink4 (37). Upon vascular injury, however, multiple response 
mechanisms are initiated, and the entry of activated VSMCs into 
the cell cycle represents the final common pathway, in which p27 
is rapidly downregulated, enabling VSMCs to resume cell divi-
Ad-p27-126TS preserved the reendothelialization process at both 
2 (Figure 4J) and 4 weeks (Supplemental Figure 6H) after injury.
We further examined reendothelialization in cross sections 
of the carotid arteries by immunostaining for VE-cadherin. Unin-
jured control vessels exhibited distinct EC staining, whereas in 
Ad-GFP–transduced arteries, which had significant neointimal 
growth, the endothelium was only minimally detectable at both 
2 and 4 weeks after injury (Figure 5, A and B, and Supplemen-
tal Figure 8, A and B). Ad-p27–transduced vessels also displayed 
diminished endothelial coverage (Figure 5, A and B, and Supple-
mental Figure 8, A and B). Crucially, in arteries transduced with 
Ad-p27-126TS, we observed a progressive and widespread reen-
dothelialization (Figure 5, A and B, and Supplemental Figure 8, A 
and B). These data strongly support our in vitro findings (Figure 
1D and Figure 2, A and B), demonstrating that overexpression 
of exogenous p27 inhibits both VSMC and EC proliferation and 
migration, whereas transduction with Ad-p27-126TS exclusively 
inhibits VSMC proliferation and migration but concurrently 
allows EC proliferation and migration, which may explain the 
reendothelialization observed in the injured vessels.
Finally, we assessed the arterial inflammatory state by 
immunostaining for CD45, a pan-inflammatory cell-surface 
marker present on all hematopoietic cells except erythrocytes 
and platelets. Both Ad-p27– and Ad-p27-126–treated vessels dis-
played a reduced arterial inflammatory response compared with 
that of uninjured controls, while we observed an intense inflam-
matory reaction in the adventitia of Ad-GFP–treated arteries 
(Supplemental Figure 9).
Ad-p27-126TS attenuates hypercoagulability in vivo. Since clini-
cal and pathological studies have reported incomplete endothelial 
coverage after PCI leading to thrombosis (12), we assessed hyper-
coagulability by measuring plasma D-dimer levels before (unin-
jured) and 3, 14, and 28 days after injury and transduction with the 
Ad vectors. All treatments showed increased D-dimer levels at day 
3, most likely in immediate response to injury (Figure 6A). Rats 
treated with Ad-GFP or Ad-p27 exhibited a significant increase in 
D-dimer levels at both 14 and 28 days after surgery (Figure 6A). 
Strikingly, in the rats treated with Ad-p27-126TS, which displayed 
complete inhibition of neointimal growth and complete reendo-
thelialization, the D-dimer levels were comparable to those of the 
uninjured animals at both 14 and 28 days after injury (Figure 6A).
Ad-p27-126TS restores EC function after arterial balloon injury. 
To evaluate endothelial function, we performed vascular reactivity 
assays (20) using carotid rings harvested from rats 2 and 4 weeks 
after injury. Carotid arteries transduced with Ad-GFP exhibited 
markedly diminished vasodilatation in response to acetylcholine 
compared with that observed in uninjured vessels, most likely due 
to restenosis (Figure 6, B and C). Ad-p27–transduced vessels also 
displayed an impaired vasodilatory response (Figure 6, B and C). 
Intriguingly, arteries transduced with Ad-p27-126TS showed nor-
mal vasodilatation, comparable to that seen in uninjured control 
vessels at both 2 and 4 weeks after injury (Figure 6, B and C). We 
observed no significant difference in the endothelium-independent 
vasodilatory response to nitroprusside (Supplemental Figure 10). 
These data are consistent with our in vitro results and with the tridi-
mensional confocal images and further confirm the integrity of the 
endothelium in Ad-p27-126–treated arteries.
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sion, thereby triggering intimal hyperplasia and leading to vascu-
lar restenosis (4). The clinical importance of a single nucleotide 
polymorphism in the p27 gene, which has been associated with an 
increased risk of myocardial infarction, underlies the central role 
of p27 in the pathophysiology of vascular remodeling (43). Over-
expression of exogenous p27 in VSMCs has been demonstrated to 
result in G1 phase arrest, leading to a significant reduction of neo-
intimal formation in a porcine femoral arterial injury model (37). 
In contrast, p27-knockout mice displayed a significant increase 
in VSMC proliferation and developed extensive arterial lesions 
(44). Furthermore, previous studies specifically evaluating the 
role of p27 overexpression in a rat carotid model of balloon angio-
plasty, like the one used here, demonstrated that the upregula-
tion of p27 led to VSMC growth arrest and attenuated neointimal 
lesion formation (36). Several reports have also demonstrated 
that sirolimus, clinically used in DES coating (1, 11, 14), blocks the 
degradation of p27, thereby preventing VSMC proliferation and 
migration (5, 8). In particular, sirolimus treatment produces an 
increase in p27 by reducing p27-targeted degradation by phos-
phorylation at Thr187 (5, 8). Thus, both p27 overexpression and 
sirolimus treatment strategies eventually result in the upregu-
lation of p27 expression (although along different pathways) to 
control VSMC cell-cycle behavior, making exogenous p27 over-
expression a means to broadly mimic treatment with sirolimus 
or its analogs used in DES. Importantly, the antiproliferative and 
antimigratory effects of sirolimus, eventually mediated by p27, 
Figure 3. Ad-p27 and Ad-p27-126TS inhibit restenosis 2 weeks after balloon injury. (A) Representative H&E-stained sections. Scale bars: 500 μm; 
original magnification, ×10 (insets show the whole arterial section at ×5 original magnification). Intima/media ratios were calculated from at least 6 rats/
group. Data represent the means ± SEM. Data comparisons were made using 1-way ANOVA with Tukey-Kramer’s post hoc test. *P < 0.01 versus uninjured 
arteries. (B) Representative sections of rat carotid arteries immunostained for α-SMA. Nuclei were counterstained with DAPI. No positive staining was 
observed in the negative control sections. Scale bars: 100 μm; original magnification, ×60 and ×120 (insets). Arrowheads indicate EC nuclei beyond the 
inner autofluorescent elastic laminae. 
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are not exclusive to VSMCs, as they have also been previously 
observed in ECs (38, 39). We therefore speculated that exogenous 
p27 overexpression would affect both VSMCs and ECs. Our data 
are in agreement with the established mechanism of action of 
p27. When transduced with Ad-p27, which does not contain miR-
126-3p target sequences, both VSMCs and ECs overexpressed 
p27 to a similar degree and exhibited similar behavior. In vitro, 
we found that exogenous p27 overexpression inhibited prolifer-
ation and migration of both VSMCs and ECs by ~70% and 75%, 
respectively, indicating that exogenous p27 overexpression has 
similar potency in regulating the cell cycle of VSMCs and ECs. 
In vivo, p27 overexpression inhibited neointimal formation. 
Figure 4. Ad-p27-126TS restores endothelial coverage of en face longitudinal arterial preparations. (A–H) Representative confocal images of the internal 
surface of the vessels immunostained for VE-cadherin. (A, C, E, and G) Tridimensional (top) and bidimensional (bottom) images of the longitudinal  
en face preparation of the carotid arteries. (B, D, F, and H) Tridimensional images of a representative central portion (see Methods and Supplemental Fig-
ure 7A for detailed information about the imaging procedure) of the vessel (top), with the respective 2D pictures showing the EC-specific immunostaining 
for VE-cadherin (bottom: VE-cadherin, DAPI, and merge) and representing the endothelial coverage, which is quantified in I; the luminal side is indicated 
by a yellow line. See also the Supplemental Videos 1–4 for a tridimensional view. Dimensional scale bars: 400 μm (all 2D and 3D images). Data comparisons 
were made using 1-way ANOVA with Tukey-Kramer’s post hoc test; n = at least 5/group. *P < 0.01 versus uninjured arteries. (J) Representative scanning 
electron microscopy images of the internal surface of uninjured, Ad-GFP–, Ad-p27–, and Ad-p27-126TS–transduced arteries. Scale bars: 10 μm.
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of miR-126-3p’s sister strand miR-126-5p, which recent evidence 
confirmed as an essential player in promoting EC proliferation 
and preventing atherosclerotic lesion formation (26). Conse-
quently, in vitro, ECs transduced with Ad-p27-126TS no longer 
demonstrated the antiproliferative and antimigratory effects 
of exogenous p27 expression. ECs exhibited preserved net-
work formation and reduced platelet adhesion compared with 
cells overexpressing exogenous p27 (Ad-p27). The inhibition of 
exogenous p27 expression in the Ad-p27-126TS treatment group 
was so effective in vitro that EC proliferation, migration, network 
formation, and platelet adhesion were restored to levels compa-
rable to those seen in controls (Ad-GFP). In vivo, we evaluated 
vascular response at 2 and 4 weeks after injury, the longer time 
course allowing for more extended evaluation of the endothelial 
repair. We found that neointimal hyperplasia was inhibited in the 
Ad-p27-126TS–treated vessels as effectively as in the Ad-p27–
treated vessels at 2 and 4 weeks after injury due to the lack of 
endogenous miR-126 in VSMCs in both groups. Hence, accord-
ing to our study, treatment with Ad-p27-126TS was as successful 
as Ad-p27 in preventing restenosis.
Remarkably, treatment with Ad-p27-126TS resulted in almost 
complete reendothelialization as soon as 2 weeks after injury 
(80%), in sharp contrast to Ad-p27 treatment, in which EC cov-
erage remained below 30% even after 1 month. We speculate 
that the endothelial coverage is triggered by EC proliferation 
Although p27 overexpression beneficially inhibited restenosis, it 
significantly impaired reendothelialization and sustained hyper-
coagulability. Indeed, we found that exogenous p27 overexpres-
sion led to a prolonged inhibitory effect on reendothelialization 
(23% and 29% endothelial coverage in Ad-p27 vessels assessed 
at 2 and 4 weeks after injury, respectively). Consistently, D-dimer 
levels were significantly higher in Ad-p27–treated rats at 2 and 4 
weeks after injury compared with levels in uninjured controls. In 
addition, Ad-p27–transduced vessels demonstrated significantly 
impaired endothelial function compared with that in uninjured 
controls. These results indicate that the inhibition of neointimal 
hyperplasia by overexpression of exogenous p27, without sparing 
ECs, fails to result in restoration of normal physiological function 
of the vessel after injury. These observations mirror the delete-
rious effects that current nonselective DES used in PCI have on 
ECs and vascular healing and are in accordance with the reported 
increased risk of thrombosis associated with DES when com-
pared with BMS (3, 12, 45, 46).
The simple incorporation of 4 miR-126-3p target sequences 
within our Ad-p27-126TS vector profoundly modulated the 
response to exogenous p27 overexpression in ECs and provided 
robust EC protection. Incorporating target sequences for just the 
mature miR-126-3p strand was distinctly advantageous, since 
we could exploit the EC specificity of miR-126, yet our target 
sequences did not serve as a sponge to diminish the bioactivity 
Figure 5. Ad-p27-126TS restores reendothelialization in cross sections of carotid 
arteries. (A) Representative sections of rat carotid arteries immunostained for the 
specific EC marker VE-cadherin 2 weeks after injury. Nuclei were counterstained with 
DAPI. No positive staining was observed in the negative control sections (Alexa Fluor 
488 alone). Scale bars: 100 μm; original magnification, ×60 and ×120 (insets). Arrow-
heads indicate ECs beyond the inner autofluorescent elastic laminae. (B) Endothelial 
coverage was quantified by counting the number of VE-cadherin–positive cells in the 
circumference of the lumens from at least 6 animals/group. Data were compared using 
1-way ANOVA with Tukey-Kramer’s post hoc test. *P < 0.05 versus uninjured arteries.
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miR-126 is enriched in 
ECs and upregulated 
in arterial injury sites 
and in atherosclerosis 
(27), we assume that 
exogenous p27 would 
be overexpressed in 
Ad-p27-126TS–trans-
duced arteries in 
VSMCs and in all the 
cell types that do not 
express miR-126. In 
this sense, exogenous 
p27 overexpression 
ultimately inhibited 
the infiltration of 
inflammatory cells to 
the injured vessel.
For the experiments presented herein, we elected to use 
an Ad delivery vehicle in a rat model of balloon angioplasty, 
a common choice for studying restenosis (34, 50–53). We are 
indeed aware that stents were not used in our animal model, 
and the time course of neointimal growth and reendotheli-
alization in rodents is more rapid than in humans, especially 
since healthy and juvenile animals normally heal within 28 
days after injury (4, 54). Nevertheless, our experimental sys-
tem was inexpensive and within our means, representing the 
most efficient approach to establishing proof-of-concept of 
our miRNA-based strategy without extensive design consider-
ations. By eliminating variables introduced by disease models, 
choice of stent platform, strut thickness, and polymer coating 
(55), we focused on the direct effects on arterial injury result-
ing from exogenous p27 overexpression and incorporation of 
miR-126-3p target sequences.
However, to translate our miRNA-based strategy to a clin-
ically relevant setting, we acknowledge that additional stud-
ies beyond the scope of this work will need to be conducted 
to assess its long-term efficacy and safety. For instance, late- 
generation adeno-associated viral (AAV) vectors could be used 
as an alternative delivery vehicle, reducing immune response 
concerns, and applied locally through gene-eluting stents or 
emerging nanotechnology-based scaffolds (21, 56). Different 
numbers of miR-126-3p target sequences may also be evalu-
ated to better modulate exogenous p27 overexpression or to 
prevent miR-126-3p target sequences from acting as a sponge 
for endogenous miR-126-3p (57). Additionally, miR-126 target 
sequences could also be used to regulate the exogenous over-
expression of alternative or additional genes of interest besides 
p27. Our miRNA-based strategy obviously needs to be evaluated 
within a stent platform as well as investigated in larger animal 
models. Ideally, future studies would be within the context of 
an atherosclerotic disease model. Indeed, an atherosclerotic 
animal model would allow us to evaluate whether the selective 
enhancement of reendothelialization and preserved EC func-
tion demonstrated by our miRNA-based strategy shows long-
term protection against neoatherosclerosis and thrombosis. 
Therefore, our strategy could potentially combine the inhibition 
and migration from sites adjacent to the injury. Endothelial pro-
genitor cells might also play a role in the reendothelialization 
process, although this notion is still controversial (47, 48). In 
Ad-p27-126TS–treated rats, we observed that reendothelializa-
tion was accompanied by a sharp decrease in plasma D-dimer 
levels to those observed in uninjured control animals as early as 
2 weeks after injury. In addition, treatment with Ad-p27-126TS 
not only reduced hypercoagulability compared with that seen in 
Ad-p27–treated rats, but restored the endothelium-dependent 
vasodilatory response to levels indistinguishable from those in 
uninjured controls. Therefore, our strategy not only reendotheli-
alized injured vessels, but did so with functional ECs. This finding 
represents a major improvement over the current state-of-the-art 
devices used for PCI, since previous studies have demonstrated 
that improving reendothelialization without improving endothe-
lial function is not enough to prevent late thrombosis (48). Given 
these results, reducing the need for prolonged dual antiplatelet 
therapy to prevent late thrombosis may be another welcome ben-
efit to CAD patients should our miRNA-based strategy show effi-
cacy in the clinical setting.
Moreover, the reendothelialization of vessels with functional 
ECs presented here may have implications for neoatherosclero-
sis. Several investigators have recently demonstrated that the 
inability to restore and maintain functional ECs following PCI 
increases the incidence of neoatherosclerosis in DES compared 
with BMS (15, 16, 41). Moreover, p27 has been shown to play a key 
role in atherosclerosis. Indeed, p27 deficiency leads to increased 
atherosclerotic plaque formation in Apoe–/– mice (49). Thus, we 
can also speculate that our strategy might prevent or inhibit 
neoatherosclerosis by targeting the cells involved in this process 
while preserving EC regeneration and promoting vessel healing. 
Further investigation is necessary to prove this particular con-
cept, which is beyond the scope of the present study.
Another strength of this study is the assessment of inflamma-
tion, an important feature in the pathophysiology of restenosis (4). 
Our data are supported by previous reports showing that p27 directly 
regulates the proliferation of bone marrow–derived cells (hemato-
poietic and nonhematopoeitic) that migrate to damaged blood 
vessels and reconstitute vascular lesions (44). Since endogenous 
Figure 6. Ad-p27-126TS reduces hypercoagulability and restores EC function in vivo. (A) Plasma D-dimer levels evaluated 
before (uninjured) and 3, 14, and 28 days after balloon injury using a specific immunoassay. n = 5 animals/group. (B and C) 
Vascular reactivity analysis on carotid rings 2 (B) and 4 (C) weeks after injury showing the vasodilatory response to acetyl-
choline (ACh). n = 5–6 rats/group. Data represent the means ± SEM and were compared using 1-way (A) or 2-way repeated
-measures (B and C) ANOVA followed by Tukey-Kramer’s post hoc test. *P < 0.01 versus uninjured arteries.
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and miR-126-5p as previously described (59). cDNA was synthesized 
by priming with miR-specific looped primers or by U18 as an endoge-
nous control. For GFP and GAPDH expression analyses, 500 ng total 
RNA was used to synthesize cDNAs using M-MuLV reverse tran-
scriptase (New England BioLabs) according to the manufacturer’s 
specifications. All reactions, excluding no-template controls and non-
reverse-transcribed controls, were run in triplicate and incubated in 
96-well plates at 95°C for 20 seconds, followed by 40 cycles of 95°C 
for 3 seconds and 60°C for 30 seconds using the ABI 7500 Fast Real 
Time PCR Detection System. RT-qPCR data were analyzed using the 
comparative CT method and normalized to the expression of U18 for 
miR-126-3p and miR-126-5p or GAPDH for GFP and PIK3R2.
Immunoblotting. Immunoblot analyses were performed as pre-
viously described (7, 35). Briefly, VSMCs and ECs were transduced 
with 30 PFU/cell. Samples were size fractionated by SDS-PAGE, and 
proteins were transferred to polyvinylidene difluoride membrane and 
visualized by immunoblotting using infrared-labeled anti-rabbit (red) 
and anti-mouse (green) secondary antibodies (1:10,000; LI-COR). 
Band intensities were quantified with the Odyssey Infrared Imaging 
System (LI-COR). The blots were probed with the following antibod-
ies: rabbit anti-GAPDH (Cell Signaling Technology); rabbit anti-GFP 
(Life Technologies, Thermo Fisher Scientific); and mouse anti-p27 
(BD Transduction Laboratories, BD Biosciences). Data are presented 
as arbitrary units after normalization to GAPDH as a loading control.
Proliferation, migration, and network formation assays. VSMCs and 
ECs were transduced with 20 or 30 PFU/cell, respectively. Prolifera-
tion assays were conducted 6 days after transduction using the Cell 
Proliferation Reagent kit (Roche Applied Science) according to the 
manufacturer’s instructions. The absorbance was measured at 450 nm 
(with a 690-nm reference wavelength) using the Infinite F500 
microplate reader (Tecan Group).
Cellular migration was assessed as previously described and val-
idated (60, 61). Briefly, a confluent cell monolayer was scraped with a 
sterile pipette tip to generate a scratch wound and washed twice with 
medium to remove cell debris. Time-lapse images were captured at 
0, 24 (ECs), and 48 hours (VSMCs). The wound areas were measured 
using ImageJ64 software (NIH). The formation of network-like struc-
tures assay was performed and quantified by counting branch points 
as previously described and then validated (60, 62). Several fields of 
view were captured per well, and experiments were repeated 3 times 
by blinded observers.
Platelet adhesion assay. Platelet adhesion was assessed in a 
parallel-plate flow chamber apparatus (GlycoTech) as previously 
described (63). Human venous whole blood samples were drawn 
into H-D-Phe-Pro-Arg-chloromethylketone (PPACK, 100 μM final 
concentration; EMD Millipore) to prevent coagulation. Whole blood 
(500 μl) was perfused at a wall shear rate of 1,600 s−1 over fibronectin- 
coated 6-well plates in which ECs had been cultured and trans-
duced (30 PFU/cell) with Ad-GFP, Ad-p27, and Ad-p27-126TS for 5 
days. Blood was perfused for 2 minutes, followed by washing with 
Tyrode’s buffer under identical flow conditions for 1 minute. Platelet 
attachment was recorded on Hi-8 videotape using a TE2000 Nikon 
microscope with a phase-contrast ×20 objective. The areas covered 
by platelets were quantified using a computerized image analysis 
system (FIJI), including 4 fields of view for each data point.
Experimental animals and in vivo balloon injury. Balloon injury of 
the right carotid artery was performed in male Sprague-Dawley rats 
of restenosis, inflammation, and neoatherosclerosis with the 
promotion of reendothelialization and vascular healing.
In summary, our findings demonstrate that it is feasible to 
use a miRNA-based strategy to combine antiproliferative and 
pro-healing mechanisms for enhanced arterial repair. Various 
therapeutic approaches have been designed to reduce neoin-
timal hyperplasia, accelerate reendothelialization, or inhibit 
thrombosis. Our strategy has the potential to achieve all of these 
objectives in a single, comprehensive treatment. Moreover, this 
approach could be exploited across multiple conditions, includ-
ing transplant vasculopathy, arteriovenous fistulae, and vein 
graft failure. The results presented here provide the basis for 
designing the next generation of selective therapy in PCI. The 
combination of a better stent platform and biodegradable poly-
mer with this selective inhibition of VSMCs, without affecting 
ECs, has the potential to revolutionize the future of vascular 
interventional medicine.
Methods
Design of Ad vectors. Recombinant Ad vectors containing p27 (Ad-
p27) and p27 with 4 tandem target sequences for hsa-miR-126-3p 
introduced at its 3′ end (Ad-p27-126TS) were constructed using 
AdEasy XL (Agilent Technologies) in accordance with the man-
ufacturer’s instructions. Briefly, p27 was amplified with primers 
5′-agtcggtaccaccATGTCAAACGTGCGAGTGTCTAACGG-3′ and 
5′-gatctgtacaggatccTTACGTTTGACGTCTTCTGAGGCC-3′ (start 
and stop codons are in bold and restriction sites in lowercase) 
and subcloned into a carrier vector. Complementary oligonucle-
otides containing 4 targeting sequences for miR-126-3p (in bold) 
(5′-aattcATCGCATTATTACTCACGGTACGAAATCCGCAT-
TATTACTCACGGTACGAA AT CCGCATTATTACTCAC-
GGTACGAA ATCCGCATTATTACTCACGGTACGAATg-3 ′ 
and 5′-aattcATTCGTACCGTGAGTAATAATGCGGATTTCG-
TACCGTGAGTAATAATGCGGATTTCGTACCGTGAGTAA-
TAATGCGGAT TTCGTACCGTGAGTAATAATGCGATg-3 ′) 
were annealed and subcloned at the 3′ end of p27 with EcoRI. Next, 
p27 and p27-126-3pTSx4 were amplified from the carrier vector 
with the following pairs of primers: 5′-agtcggtaccaccATGTCAAAC-
GTGCGAGTGTCTAACGG-3′ as a sense primer for both con-
structs, and 5′-agtcctcgagTTACGTTTGACGTCTTCTGAGGCC-3′ 
and 5′-agtcctcgagaTTCGTACCGTGAGTAATAATGCGGATTTC-3′ 
as antisense primers for p27 and p27-126-3pTSx4, respectively. The 
resulting PCR products were subcloned into a pAdTrack-CMV shut-
tle vector (using Acc65 I and Xho I restriction sites, shown in lower-
case) under the control of a CMV promoter. All the constructs also 
contained a GFP under the control of a CMV promoter. All final Ad 
constructs were confirmed by sequencing, purified by ultracentrifu-
gation in CsCl gradient, dialyzed, and titrated in human embryonic 
kidney (HEK) cells (58).
Cell culture. Human umbilical venous ECs were cultured in EGM2 
Bullet Kit medium (Lonza Group) on dishes coated with type I rat tail 
collagen (VWR International). Human VSMCs and SmGM-2 Bullet 
Kit medium were purchased from Lonza Group. The cells in all assays 
were below passage 6 and cultured at a density that allowed cell divi-
sion throughout the course of the experiments.
RT-qPCR. TaqMan microRNA Assays (Life Technologies, 
Thermo Fisher Scientific) were used to quantify mature miR-126-3p 
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lated using ImageJ64 software as previously described (34). Cross-
section images were acquired with a Nikon A1 scanning confocal 
microscope, and the number of VE-cadherin–positive cells in the 
circumference lumen was quantified.
Scanning electron microscopy. Longitudinal en face vascular prepa-
rations were fixed with 2.5% glutaraldehyde and 2 mM CaCl2 in 75 mM 
Na-cacodylate buffer for at least 30 minutes. The tissues were rinsed 
in the buffer and washed in water for 15 minutes 3 times and subjected 
to a freeze-dry procedure: each vessel was plunged into precooled 
ethane, transferred into liquid nitrogen, slowly dried for 20 hours in a 
chamber (Leica EM AFS) in the presence of vapor-phase liquid nitro-
gen, and subjected to critical-point drying. The dried tissue was coated 
with a thin gold palladium layer using an ion spatter (Denton Desk IV 
Coater, Denton Vacuum) and examined under a scanning electron 
microscope (LEO 1550; Carl Zeiss) with a field-emission electron gun 
and SmartSEM version 5 software.
Vascular reactivity. Two and 4 weeks after injury, the rats were 
euthanized, and the common carotid arteries were quickly har-
vested and suspended in isolated tissue baths filled with 25 ml 
Krebs-Henseleit solution (118.3 mM NaCl, 4.7 mM KCl, 2.5 mM 
CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25 mM NaHCO3, and 
5.6 mM glucose) continuously bubbled with a mixture of 5% CO2 
and 95% O2 (pH 7.38–7.42) at 37°C as previously described (65). 
Endothelium-dependent vasorelaxation was assessed in vessels 
preconstricted with phenylephrine (10–5 M) in response to acetyl-
choline from 10–9 to 10–6 M, as previously described (20, 64). Nitro-
prusside (from 10–9 to 10–6 M) was used to evaluate the endotheli-
um-independent response (20). All drugs were freshly prepared on 
the day of the experiment. Concentrations are reported as the final 
molar value in the organ bath.
Statistics. Data are expressed as the mean ± SEM. One- or 2-way 
ANOVA was performed, as appropriate, with Tukey-Kramer’s post 
hoc correction. All analyses were performed using GraphPad Prism 
5.0 software. Specific tests and significance levels are reported in 
the figure legends. P < 0.05 was considered statistically significant.
Study approval. The IACUC of Columbia University Medical Cen-
ter approved all animal study procedures. Human venous whole blood 
samples for the platelet adhesion assay were obtained from volunteers 
who provided signed, informed consent, according to Columbia Uni-
versity IRB protocols and Declaration of Helsinki principles.
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(weighing 300 ± 35 g; Harlan Laboratories) using a HyperGlide bal-
loon catheter (Micro Therapeutics) as previously described (34). The 
animals were anesthetized by isoflurane (4%) inhalation and main-
tained by mask ventilation (isoflurane 2%), and the right common, 
external, and internal carotid arteries were exposed and isolated. 
Through the external carotid artery, the balloon catheter was intro-
duced into the common carotid artery and inflated 7 times. After 
injury, the common carotid artery was flushed twice with PBS, and a 
solution of PBS and Ad (5 × 109 PFU/100 μl) was injected and allowed 
to incubate in the common carotid artery in the absence of flow for 20 
minutes. During this procedure, the tension of the common carotid 
artery was maintained by placing microvascular clips (Harvard Appa-
ratus) on the internal and common carotid arteries (64). The Ad was 
then removed by aspiration. The external carotid artery was tied, and 
blood flow was restored through the common and internal carotid 
arteries. Following wound closure, the rats were given ad libitum 
access to food and water. The animals were housed in a 22°C room 
with a 12-hour light/12-hour dark cycle. All experiments were per-
formed by blinded investigators.
D-dimer measurement. Hypercoagulability was assessed by mea-
suring D-dimer plasma levels using a rat-specific ELISA Kit for D-dimer 
(USCN Life Science) according to the manufacturer’s instructions.
Immunofluorescence. Two and 4 weeks after surgery, the rats 
were euthanized and perfused at 100 mmHg with 100 ml PBS, fol-
lowed by 80 ml PBS containing 4% paraformaldehyde via a can-
nula placed in the cardiac left ventricle. For en face longitudinal 
arterial preparations, both right and left common carotid arteries 
were isolated, excised, fixed overnight with 4% paraformaldehyde 
and 20% sucrose, glued to a coverslip, and immunostained with 
VE-cadherin (1:100; Abcam) specific to ECs (40) for 1 hour at room 
temperature. Cy3-labeled secondary antibody (1:1,000; Abcam) 
was incubated at room temperature for 30 minutes, followed by 
DAPI staining (Thermo Fisher Scientific). After proper washes, 
tridimensional images and videos of longitudinal en face vessels 
were obtained by assembling 10 high-resolution images of multi-
ple z stacks taken with a Nikon A1 scanning confocal microscope 
(Nikon Instruments) and acquired with NIS-Elements (Nikon 
Instruments) advanced research software. Images were optimized 
for contrast, without any further manipulation. Quantification of 
the endothelial coverage was performed by counting the red areas 
(VE-cadherin staining) of the central portion of the artery using 
ImageJ64 software. A schematic representation of the procedure is 
shown in Supplemental Figure 7A.
For the cross-section images, the arteries were excised as 
described above and embedded in OCT medium (Sakura Finetek 
USA) for cryosectioning. Subsequently, 10-μm sections were cut 
every 20 μm and submitted in toto for histological evaluation. Sec-
tions were processed for staining with the following antibodies: 
anti–α-SMA (Cy3-conjugated α-SMA, 1:1,000 for 3 hours at room 
temperature; Sigma-Aldrich), anti–VE-cadherin (1:100 overnight 
at 4°C; Abcam), and anti-GFP (1:1,000 overnight at 4°C; Thermo 
Fisher Scientific). Fluorescent-labeled secondary antibodies 
(1:1,000; Thermo Fisher Scientific) were incubated at room temper-
ature for 1 hour (Alexa Fluor 488 was used for VE-cadherin detec-
tion and Cy3 for GFP detection). Samples were then washed with 
PBS and mounted with SlowFade Gold antifade reagent with DAPI 
(Thermo Fisher Scientific). Neointima/media ratios were calcu-
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Effect of Ad-p27-126TS on the expression of miR-126-3p, PIK3R2 and miR-126-5p 
in vitro. 
EC were infected with the indicated adenoviruses for 24 h. Total RNA was extracted, 
and real time RT-qPCR for 126-3p (A), PIK3R2 (B), and miR-126-5p (C) was 
performed. Expression levels of miRNAs were normalized to U18, PIK3R2 was 
normalized to GAPDH. Data shown are means±SE; *p<0.05 vs Ad-GFP, one-way 
ANOVA, Tukey-Kramer post hoc test.  
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Figure S2 
 
Efficiency of Ad infection two and four weeks after surgery. 
The efficiency of Ad infection was evaluated 2 (A) and 4 weeks after surgery (B) using 
a primary antibody against GFP detected using a Cy3-coniugated secondary antibody. 
Representative digital images are shown. In A, top: negative control (secondary 
antibody alone, Cy3); bottom: staining for GFP revealed by Cy3. Scale bar represents 
100 µm (magnification 60×).  
Santulli G. et al. 




Assessment of p27 
overexpression in the carotid 
wall three days after surgery. 
Three days after infection with 
the indicated Ad constructs the 
vessels were homogenized and 
samples were size-fractionated 
by SDS-PAGE; proteins were 
transferred to polyvinylidene 
difluoride membrane and 
visualized by immunoblotting 
using infrared-labeled 
antibodies. Data shown in the 
graph represents means±SE; 
*p<0.05 vs Ad-GFP, one-way 
ANOVA, Tukey-Kramer post hoc 
test. 
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Figure S4  
 
Ad-p27 and Ad-p27-126TS inhibit restenosis 4 weeks after balloon injury.  
Representative sections stained with hematoxylin / eosin (magnification 40×; 
dimensional bar represents 100 µm). Intima/media ratios were calculated from at least 
6 rats/group. All data shown are means ± SEM. Data comparisons were made using 
one way ANOVA followed by Tukey-Kramer post hoc test; *P<0.01 versus Ad-GFP.
Santulli G. et al. 




Ad-p27 and Ad-p27-126TS restored the arterial structure to the uninjured control vessel.  
Representative sections stained with (A) Masson's Trichrome to detect collagen fibers or (B) Verhoeff Van Gieson to 
detect elastin fibers (magnification 40×; dimensional bar represents 100 µm). 
 
  
Santulli G. et al. 




Endothelial coverage assessed by confocal electron microscopy of en face longitudinal arterial preparations 4 
weeks after injury.  
(A-F) Representative confocal images of the internal surface of the vessels immunostained for VE-Cadherin acquired at 
the. (A, C, E) Tridimensional (top) and bidimensional (bottom) imaging of the longitudinal en face preparation of the 
carotid arteries. (B, D, F) Tridimensional imaging of a representative central portion (see the methods and 
Supplementary Fig. 7A for detailed information about the imaging procedure) of the vessel (top), with the respective 2D 
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pictures showing the EC-specific immunostaining for VE-cadherin (bottom: VE-cadherin, DAPI and merge, as indicated), 
representing the endothelial coverage, which is quantified in panel G; the luminal side is indicated by the yellow line; see 
also the Supplementary videos 5-7 for a tridimensional view. In all 2D and 3D pictures the dimensional bar is 400 µm. All 
data shown are means ± SEM. Data comparisons were made using one-way ANOVA with Tukey-Kramer post hoc test; n 
= at least 5/group; *P<0.01 versus uninjured. (H) Representative scanning electron microscopy (SEM) images of the 
internal surface of uninjured, Ad-GFP, Ad-p27 and Ad-p27-126TS infected arteries. In SEM pictures, the scale bar 
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Figure S7 
 
Imaging and quantifications of the longitudinal en face arterial preparations. 
(A) Schematic representation of the examination of en face preparations at the confocal microscope. Ten adjacent 
quadrants of each carotid artery were independently scanned and subsequently 3D reconstructed using a dedicated 
software (Nikon NIS-Elements) to obtain the image of the whole vessel. The quantification of the endothelial coverage 
(VE-Cadherin staining) was performed quantifying the red areas of the central portion of the artery (represented by bold 
dashed lines, quadrants 3 and 8) by using ImageJ64. (B) No specific staining is shown (20× magnification, confocal 
microscope) in the whole uninjured vessel stained with the Cy3 secondary antibody alone. Tridimensional (top) and bi-
dimensional (bottom) imaging of the longitudinal en face preparation of the carotid artery is depicted. (C) Tridimensional 
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imaging (top) of a representative central portion of the vessel, with the respective 2D pictures (bottom) showing the 
immunostaining for Cy3, DAPI and merge, as indicated. See the supplementary video 8 A and B relative to the 3D 
images of the samples. Scale bar: 400 µm. 
 
  
Santulli G. et al. 




Ad-p27-126TS restores re-endothelialization in cross sections of injured carotid arteries. 
(A) Representative sections of rat carotid arteries immunostained for the specific EC marker VE-Cadherin 4 weeks after 
injury. Nuclei were counterstained with DAPI. Orange scale bars: 100 µm (magnification 60×, inlays show high 
magnification images), arrowheads indicate EC beyond the inner autofluorescent elastic laminae. (B) Quantification of 
endothelial coverage was performed by counting the number of VE-cadherin positive cells in the circumference lumen 
from 6 sections/group. All data shown are means ± SEM. Data comparison was performed using one-way ANOVA, 
Tukey-Kramer post hoc test.  
 






Ad-p27 and Ad-p27-126TS inhibit arterial inflammation 2 weeks after 
balloon injury.  
Representative sections of rat carotid arteries immunostained for CD45, 2 weeks 
after injury. Nuclei were counterstained with DAPI. No positive staining was 
observed in the negative control sections (Cy3 alone). White scale bars: 100 µm 
(magnification 40×). CD45 positive cells were quantified by counting the number 
of CD45 positive cells in the intimal and medial areas from at least 3 
sections/group. Data comparison was made using one way ANOVA, Tukey-
Kramer post hoc test; *P<0.05 versus uninjured.  
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Figure S10 
Vasodilatory response of carotid arteries to nitroprusside.  
Carotid rings 2 weeks after injury showing the vasodilatative response to 
nitroprusside. n=5-6 rats/group. All the data are means ± SEM.  
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Video Legends 
 
Supplementary Video 1  
Uninjured vessel. 
This video refers to Figure 4AB. Representative tridimensional reconstruction of 
a longitudinal en face preparation (A) of an uninjured rat carotid artery 
immunostained with VE-cadherin (revealed by a Cy3 conjugated secondary 
antibody) and acquired at the confocal microscopy after assembling distinct 
portions of the vessel [the acquisition of the central portion of the artery is shown 
in B] each obtained from a high resolution focal stack of 2D images using 
sequential refocusing. In B, the EC-specific immunostaining for VE-cadherin of a 
central portion of the vessel is shown in red (Cy3), followed by DAPI staining and 
then the merge (Cy3/DAPI).  
 
Supplementary Video 2  
Ad-GFP infected rat carotid artery two weeks after injury. 
This video refers to Figure 4 CD. Representative tridimensional reconstruction of 
a longitudinal en face preparation (C) of an Ad-GFP infected rat carotid artery 
two weeks after injury immunostained with VE-cadherin (revealed by a Cy3 
conjugated secondary antibody) and acquired at the confocal microscopy after 
assembling distinct portions of the vessel [the acquisition of the central portion of 
the artery is shown in D] each obtained from a high resolution focal stack of 2D 
images using sequential refocusing. In D, the EC-specific immunostaining for VE-
cadherin of a central portion of the vessel is shown in red (Cy3), followed by 
DAPI staining and then the merge (Cy3/DAPI).  
 
Supplementary Video 3 
Ad-p27 infected rat carotid artery two weeks after injury. 
This video refers to Figure 4 EF. Representative tridimensional reconstruction of 
a longitudinal en face preparation (E) of an Ad-p27 infected rat carotid artery two 
weeks after injury immunostained with VE-cadherin (revealed by a Cy3 
conjugated secondary antibody) and acquired at the confocal microscopy after 
assembling distinct portions of the vessel [the acquisition of the central portion of 
the artery is shown in F] each obtained from a high resolution focal stack of 2D 
images using sequential refocusing. In F, the EC-specific immunostaining for VE-
cadherin of a central portion of the vessel is shown in red (Cy3), followed by 
DAPI staining and then the merge (Cy3/DAPI). 
 
Supplementary Video 4 
Ad-p27-126TS infected rat carotid artery two weeks after injury. 
This video refers to Figure 4 GH. Representative tridimensional reconstruction of 
a longitudinal en face preparation (G) of an Ad-p27-126TS infected rat carotid 
artery two weeks after injury immunostained with VE-cadherin (revealed by a 
Cy3 conjugated secondary antibody) and acquired at the confocal microscopy 
after assembling distinct portions of the vessel [the acquisition of the central 
portion of the artery is shown in H] each obtained from a high resolution focal 
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stack of 2D images using sequential refocusing. In H, the EC-specific 
immunostaining for VE-cadherin of a central portion of the vessel is shown in red 
(Cy3), followed by DAPI staining and then the merge (Cy3/DAPI).  
 
Supplementary Video 5 
Ad-GFP infected rat carotid artery four weeks after injury. 
This video refers to Figure S5 AB. Representative tridimensional reconstruction 
of a longitudinal en face preparation (A) of an Ad-GFP infected rat carotid artery 
four weeks after injury immunostained with VE-cadherin (revealed by a Cy3 
conjugated secondary antibody) and acquired at the confocal microscopy after 
assembling distinct portions of the vessel [the acquisition of the central portion of 
the artery is shown in B] each obtained from a high resolution focal stack of 2D 
images using sequential refocusing. In B, the EC-specific immunostaining for VE-
cadherin of a central portion of the vessel is shown in red (Cy3), followed by 
DAPI staining and then the merge (Cy3/DAPI).  
 
Supplementary Video 6 
Ad-p27 infected rat carotid artery four weeks after injury. 
This video refers to Figure S5 CD. Representative tridimensional reconstruction 
of a longitudinal en face preparation (C) of an Ad-p27 infected rat carotid artery 
four weeks after injury immunostained with VE-cadherin (revealed by a Cy3 
conjugated secondary antibody) and acquired at the confocal microscopy after 
assembling distinct portions of the vessel [the acquisition of the central portion of 
the artery is shown in D] each obtained from a high resolution focal stack of 2D 
images using sequential refocusing. In D, the EC-specific immunostaining for VE-
cadherin of a central portion of the vessel is shown in red (Cy3), followed by 
DAPI staining and then the merge (Cy3/DAPI). 
 
Supplementary Video 7 
Ad-p27-126TS infected rat carotid artery four weeks after injury. 
This video refers to Figure S5 EF. Representative tridimensional reconstruction 
of a longitudinal en face preparation (E) of an Ad-p27-126TS infected rat carotid 
artery four weeks after injury immunostained with VE-cadherin (revealed by a 
Cy3 conjugated secondary antibody) and acquired at the confocal microscopy 
after assembling distinct portions of the vessel [the acquisition of the central 
portion of the artery is shown in F] each obtained from a high resolution focal 
stack of 2D images using sequential refocusing. In F, the EC-specific 
immunostaining for VE-cadherin of a central portion of the vessel is shown in red 
(Cy3), followed by DAPI staining and then the merge (Cy3/DAPI). 
 
Supplementary Video 8 
Negative control (Secondary antibody alone). 
This video refers to Figure S7B and C. Representative tridimensional 
reconstruction of a longitudinal en face preparation of an uninjured rat carotid 
artery (stained with a Cy3 conjugated secondary antibody alone, as negative 
control) and acquired at the confocal microscopy after assembling distinct 
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portions of the vessel [the acquisition of the central portion of the artery is shown 
in C] each obtained from a high resolution focal stack of 2D images using 
sequential refocusing. In C, a central portion of the vessel incubated with the Cy3 
conjugated secondary alone is shown, followed by DAPI and merge.  
 
